In COVID-19 clinical update #92, Dr. Griffin reviews emerging data on the Omicron variant, much information about monoclonal antibody treatment, including expansion of EUA for Lilly’s cocktail, FDA EUA for pre-exposure prophylaxis, outcomes after treatment, and investigation of subcutaneous or intramuscular administration; effect of adding immunomodulatory agents to usual care on thromboembolic events, and long COVID following infection in previously vaccinated individuals.

Hosts: Daniel Griffin and Vincent Racaniello

Subscribe (free): iTunes, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Risk associated with Omicron (medRxiv)
• Expansion of monoclonal EUA (FDA)
• Neutralization of Omicron by sera (medRxiv)
• Third dose sera neutralize Omicron (Pfizer)
• Monoclonals authorized for PreP (FDA)
• Patient outcomes after monoclonals (Open Forum Inf Dis)
• Subcutaneous or intramuscular monoclonals (medRxiv)
• WHO does not recommend convalescent serum (WHO)
• Immunomodulation and thromboembolic risk (J Clin Med)
• Long COVID after infection of vaccinated (medRxiv)
• Letters read on TWiV 840
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]